Hepatocellular carcinoma: A real-life experience in a specialized center in Bogotá, Colombia

Prieto-Ortiz, Jhon Edison; Garzón-Orjuela, Nathaly; Sánchez-Pardo, Santiago; Prieto-Ortiz, Robin Germán; Eslava-Schmalbach, Javier.
Rev. colomb. gastroenterol ; 37(2): 163-172, Jan.-June 2022. tab, graf
Artículo en Inglés, Español | LILACS | ID: biblio-1394945

Documentos relacionados

  1. [Status Quo and Development of Immunotherapy for Hepatocellular Carcinoma].
  2. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma.
  3. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
  4. Vascular response patterns to targeted therapies in murine breast cancer models with divergent degrees of malignancy.
  5. Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2.
  6. [A new hope in the treatment of hepatocellular carcinoma].
  7. Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas.
  8. Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
  9. Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center.
  10. Systemic Therapy in Metastatic Hepatocellular Carcinoma.